For thyroid cancer cells resistant to 131I, low expression of MEG3 means increased expression of miR-182 and promotion of cell proliferation, which is detrimental to the treatment effect of 131I for thyroid cancer (Liu et al., 2018). This evidence concerns the gene MEG3 and thyroid gland carcinoma.